Mycobutin (Rifabutin)

Rifabutin, the active ingredient in Mycobutin, is a rifamycin presented as an oral formulation for systemic use. It is employed in the treatment and prevention of infections caused by Mycobacterium avium complex and Mycobacterium tuberculosis, particularly in patients with compromised immune systems such as those living with HIV.

GNH USA supplies Mycobutin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is distributed through regulated channels to ensure consistent potency and safety.

Mycobutin is a rifamycin used to manage mycobacterial infections, especially in immunocompromised patients. - Mycobacterium avium complex (MAC) infection: reduces bacterial load and improves clinical outcomes in immunocompromised patients. - Pulmonary tuberculosis: contributes to bacterial eradication as part of combination therapy. - Tuberculosis prophylaxis in HIV‑positive individuals: lowers risk of active disease when used with other agents.

Adverse reactions may occur with rifabutin therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often transient. - Abdominal pain: discomfort in the stomach area. - Rash: mild skin eruption. - Headache: occasional dull headache. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Uveitis: inflammation of the eye that may affect vision.

Before initiating Mycobutin, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly during therapy. - HIV patients: watch for immune reconstitution inflammatory syndrome. - Drug interactions: review all concomitant medications for potential interactions. - Pregnancy and lactation: evaluate risk versus benefit before use. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Rifabutin may interact with several drug classes; categorize interactions by clinical significance.

Major Interactions (Avoid): - Protease inhibitors (e.g., ritonavir): may increase rifabutin levels, risking toxicity. - Macrolide antibiotics (e.g., clarithromycin, azithromycin): can raise rifabutin concentrations. - Antiretroviral agents (e.g., efavirenz): may reduce rifabutin efficacy. - Anticoagulants (e.g., warfarin): enhanced anticoagulant effect leading to bleeding. - Anticonvulsants (e.g., carbamazepine, phenytoin): may lower rifabutin levels, reducing effectiveness.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduced contraceptive efficacy. - Fluoroquinolones: additive risk of QT interval prolongation. - Immunosuppressants (e.g., cyclosporine): may require dose adjustment. - Statins (e.g., simvastatin): increased risk of myopathy. - Methotrexate: potential for heightened toxicity.